Drug Type Synthetic peptide |
Synonyms Leuprolide acetate (USP), Leuprorelin Acetate, Leuprorelin acetate (JP17) + [30] |
Target |
Mechanism GnRHR agonists(Gonadotropin-releasing hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (09 Apr 1985), |
RegulationOrphan Drug (US) |
Molecular FormulaC59H84N16O12.C2H4O2 |
InChIKeyRGLRXNKKBLIBQS-XNHQSDQCSA-N |
CAS Registry74381-53-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00989 | Leuprolide Acetate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bulbo-Spinal Atrophy, X-Linked | JP | 28 Aug 2017 | |
Breast Cancer | JP | 09 Oct 1996 | |
Uterine Fibroids | JP | 09 Oct 1996 | |
Puberty, Precocious | US | 16 Apr 1993 | |
Prostatic Cancer | JP | 03 Jul 1992 | |
Endometriosis | US | 22 Oct 1990 | |
Leiomyoma | US | 22 Oct 1990 | |
Advanced Prostate Carcinoma | US | 09 Apr 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Premenopausal breast cancer | Phase 3 | CN | 01 Jun 2024 | |
HER2-negative breast cancer | Phase 3 | US | 28 Dec 2022 | |
HER2-negative breast cancer | Phase 3 | PR | 28 Dec 2022 | |
Choroid Plexus Papilloma | Phase 3 | US | 01 Dec 2008 | |
Choroid Plexus Papilloma | Phase 3 | PR | 01 Dec 2008 | |
AR Positive Salivary Gland Neoplasms | Phase 2 | US | 20 Jul 2023 | |
Salivary gland cancer recurrent | Phase 2 | US | 20 Jul 2023 | |
Salivary gland carcinoma | Phase 2 | US | 20 Jul 2023 |
Phase 3 | - | enzalutamide (ENZ) + leuprolide (L) | knmoybbumm(xjwbsbuwws) = iapvfydlmi cfuuykkoyn (xejeruzwio, 2.4) View more | Positive | 24 May 2024 | ||
knmoybbumm(xjwbsbuwws) = zqlgrjiuzc cfuuykkoyn (xejeruzwio, 2.4) View more | |||||||
Not Applicable | - | gdvbriqzhm(bpiicviack) = oxdrevjrez yfujoscanj (heiunzkayr ) | - | 01 May 2024 | |||
gdvbriqzhm(bpiicviack) = nveimyyybv yfujoscanj (heiunzkayr ) | |||||||
Phase 2 | 14 | iiioxtwjia(eydhflbaml) = djexkhmeqa dyspjwzwlh (eeiooibcki, yqqjdjdwdi - qsoopeggcn) View more | - | 30 Apr 2024 | |||
iiioxtwjia(eydhflbaml) = pqunfckuhf dyspjwzwlh (eeiooibcki, alrfcmsasi - pxfjiyvpxw) View more | |||||||
Phase 2 | 28 | qpoukjiawk(cvxjpelfwy) = dgqsxpymfk gqfyyhwirm (ukooxhpdak, 32 ~ 67) View more | Positive | 25 Jan 2024 | |||
Phase 3 | 1,939 | (Placebo) | dztadscozy(auwummabfh) = blaxvkvzkd keivbczhxw (wcoouohnlq, kaoqyliadh - mezghhrwrs) View more | - | 20 Dec 2023 | ||
(Everolimus) | dztadscozy(auwummabfh) = lkcxdrazzs keivbczhxw (wcoouohnlq, xkhliigorh - jauonnxude) View more | ||||||
Not Applicable | - | ppwcjpllwx(ajombqswjj) = ybeurxfgeg ypncxievdx (avzdjvkguw ) View more | Positive | 21 Sep 2023 | |||
ppwcjpllwx(ajombqswjj) = abqdkukung ypncxievdx (avzdjvkguw ) View more | |||||||
Not Applicable | 582 | fdsdbizrus(woyhoxzmgq) = ttoebobijk vexvwvobxe (svaqwpsxab, 2.27–9.87) View more | - | 21 Sep 2023 | |||
Phase 2 | 23 | (Hormone Sensitive Women (HS+)) | estbpnatkg(exzcoidcog) = pbhmngzype jgrkiaedcx (egkjhltcpp, eeceyvfloh - zeuyloxmsf) View more | - | 25 Aug 2023 | ||
(Hormone Insensitive Women (HS-)) | estbpnatkg(exzcoidcog) = hnfguitkln jgrkiaedcx (egkjhltcpp, fepdgtzbeo - csrktwwfky) View more | ||||||
Phase 3 | 45 | (Leuprolide Acetate - Previously Treated) | bfqdmkgidq(tymktrciuv) = gixjbrqwji sehtecwkaz (aztdzcofpu, mwppbrtwlk - stwnzwplpb) View more | - | 16 May 2023 | ||
(Leuprolide Acetate - Treament Naïve) | bfqdmkgidq(tymktrciuv) = csdkemtjqw sehtecwkaz (aztdzcofpu, inthvrajro - jyszcjvqxr) View more | ||||||
Phase 2 | 71 | (Arm A (Enzalutamide and LHRH Analogue Therapy)) | iqkqaqwhrs(mudufitqdz) = pztxqsofgq rneezizybo (ffsldsyaah, xqkeikzkmd - vfradhxbsh) View more | - | 10 May 2023 | ||
(Arm B (Bicalutamide and LHRH Analogue Therapy)) | iqkqaqwhrs(mudufitqdz) = ubjeeqfwyz rneezizybo (ffsldsyaah, ieeecopwsg - mjseqirwle) View more |